Philadelphia-based oncology company FORE Biotherapeutics recently closed on an upsized $67.4 million Series D-2 extension financing, bringing the total Series D-2 funding raised to $110 million. Proceeds will be used to support the ongoing late-stage development of plixorafenib, its lead cancer drug candidate.
Plixorafenib is a BRAF inhibitor designed to address treatment gaps from first and second generation BRAF inhibitors. The U.S. Food and Drug Administration granted the drug a Breakthrough Therapy Designation in April, and it has demonstrated favorable results in drug studies.
“We are pleased with the progress at Fore this year, which allowed us to expand our investor base with new, quality healthcare investors and are grateful for the continued support from all our existing investors, which reflects their confidence in the potential for plixorafenib to disrupt the BRAF market,” William Hinshaw, Fore CEO, said. “With target enrollment now complete in the primary CNS tumor basket, we look forward to reporting topline data from this basket around the end of 2026. With the recent Breakthrough Therapy Designation granted to plixorafenib, we continue to progress towards a planned regulatory submission in 2027 for BRAF V600E CNS tumors and bringing this novel mechanism and differentiated profile to patients who are in need of improved therapeutic options.”